Lyric buys Concert to bolster its Lyric42 healthcare decision platform
What's the deal? Lyric, a healthcare decision intelligence company focused on payment accuracy, has acquired ConcertDealroom has a profile for this one. Try Dealroom →, a precision health payment accuracy firm whose technology translates machine-readable policies into real-time decisions. Terms were not disclosed. Concert's capabilities will be folded into Lyric42, Lyric's healthcare decision intelligence platform.
Why now? Health plans face pressure to control rising costs while keeping pace with fast-moving clinical evidence, from genetic testing to new therapies. Lyric frames the deal as a way to meet those demands by uniting policy, data, and decision-making in systems that plans and providers already use.
What's the endgame? Lyric is building what it calls the most powerful decision intelligence platform in the market. Concert brings a decade-old method for building machine-readable clinical policy, which Lyric plans to scale through Lyric42.
What changes? The two companies have worked together since 2023, with their joint solution growing nearly tenfold over that period. Their Diagnostics Module now handles policy and claim editing for all outpatient laboratory testing, with further expansion planned. The acquisition extends that across Lyric's client base.
"Combining with Lyric allows us to deliver at scale through the Lyric42 platform," said Rob MetcalfDealroom has a profile for this one. Try Dealroom →, Concert's chief executive officer. "Together, we can extend intelligence across the workflows where healthcare decisions are made."
Lyric president and chief financial officer Ravi UmarjiDealroom has a profile for this one. Try Dealroom → said the deal shifts the model "from reactive enforcement at disconnected checkpoints to shared standards," aligning health plans, providers, and members.
The signal: As advanced diagnostics and personalised therapies reshape care, payment accuracy vendors are consolidating to embed clinical policy directly into claims workflows. "Healthcare decision intelligence will define the next decade of this industry," said Lyric chief executive officer Halsey WiseDealroom has a profile for this one. Try Dealroom → — and this deal is Lyric's bid to lead it.
Read more: AP News
Image credit: qubodup
